Efficacy of anti-PD-1 antibody SHR-1210 as second-line treatment in hepatocellular carcinoma patient with sorafenib resistance A case report

Zhu, H; Yang, X; Zhao, YQ; Yi, C

Zhu, H (reprint author), Sichuan Univ, West China Hosp, Canc Ctr, Dept Med Oncol, Chengdu 610041, Sichuan, Peoples R China.

MEDICINE, 2019; 98 (20):

Abstract

Rationale: Hepatocellular carcinoma (HCC), one of the most common cancers worldwide, is an aggressive tumor with very poor prognosis. Regorafenib was ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索